{
  "id": "doac_score",
  "title": "Direct-Acting Oral Anticoagulants (DOAC) Score",
  "description": "Predicts bleeding risk in patients with atrial fibrillation on direct-acting oral anticoagulants",
  "category": "cardiology",
  "version": "2023",
  "parameters": [
    {
      "name": "age_category",
      "type": "string",
      "required": true,
      "description": "Patient age category for bleeding risk assessment",
      "options": ["under_65", "65_to_69", "70_to_74", "75_to_79", "80_or_over"],
      "validation": {
        "enum": ["under_65", "65_to_69", "70_to_74", "75_to_79", "80_or_over"]
      }
    },
    {
      "name": "creatinine_clearance_category",
      "type": "string",
      "required": true,
      "description": "Creatinine clearance category",
      "options": ["over_60", "30_to_60", "under_30"],
      "validation": {
        "enum": ["over_60", "30_to_60", "under_30"]
      }
    },
    {
      "name": "underweight",
      "type": "string",
      "required": true,
      "description": "BMI <18.5 kg/mÂ²",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "stroke_tia_embolism_history",
      "type": "string",
      "required": true,
      "description": "History of stroke, TIA, or systemic embolism",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "diabetes",
      "type": "string",
      "required": true,
      "description": "Diabetes mellitus",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "hypertension",
      "type": "string",
      "required": true,
      "description": "Hypertension",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "antiplatelet_use",
      "type": "string",
      "required": true,
      "description": "Current antiplatelet agent use (aspirin, clopidogrel, etc.)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "nsaid_use",
      "type": "string",
      "required": true,
      "description": "Current NSAID use",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "bleeding_history",
      "type": "string",
      "required": true,
      "description": "History of major bleeding",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "liver_disease",
      "type": "string",
      "required": true,
      "description": "Liver disease",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    }
  ],
  "result": {
    "name": "doac_score",
    "type": "integer",
    "unit": "points",
    "description": "Total DOAC score (range 0-10)"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 3,
        "stage": "Very Low",
        "description": "Very low bleeding risk",
        "interpretation": "Very low bleeding risk. Patient may continue DOAC therapy with standard monitoring. Annual bleeding rate approximately 0.3-0.8%."
      },
      {
        "min": 4,
        "max": 5,
        "stage": "Low",
        "description": "Low bleeding risk",
        "interpretation": "Low bleeding risk. Patient may continue DOAC therapy with standard monitoring. Annual bleeding rate approximately 1.1-1.9%."
      },
      {
        "min": 6,
        "max": 7,
        "stage": "Moderate",
        "description": "Moderate bleeding risk",
        "interpretation": "Moderate bleeding risk. Consider more frequent monitoring and bleeding risk reduction strategies. Annual bleeding rate approximately 2.5-4.1%."
      },
      {
        "min": 8,
        "max": 9,
        "stage": "High",
        "description": "High bleeding risk",
        "interpretation": "High bleeding risk. Consider bleeding risk reduction strategies, more frequent monitoring, and evaluate risk-benefit ratio. Annual bleeding rate approximately 5.2-8.1%."
      },
      {
        "min": 10,
        "max": 10,
        "stage": "Very High",
        "description": "Very high bleeding risk",
        "interpretation": "Very high bleeding risk. Careful evaluation of risk-benefit ratio required. Consider bleeding risk reduction strategies and frequent monitoring. Annual bleeding rate approximately 10.8%."
      }
    ]
  },
  "references": [
    "Aggarwal A, Wang TY, Rumsfeld JS, et al. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation. 2023 Nov 7;148(19):1482-1492. doi: 10.1161/CIRCULATIONAHA.123.064556.",
    "Costa OS, Beyer-Westendorf J, Ashton V, et al. Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: A report from a prospective European observational registry. Thromb Res. 2024 Aug;240:109063. doi: 10.1016/j.thromres.2024.109063."
  ],
  "formula": "DOAC Score = Age points + Creatinine clearance points + Sum of risk factors (underweight, stroke/TIA/embolism history, diabetes, hypertension, antiplatelet use, NSAID use, bleeding history, liver disease). Maximum score is capped at 10 points.",
  "notes": [
    "Developed specifically for patients on direct oral anticoagulants (DOACs)",
    "Superior performance compared to HAS-BLED score in DOAC-treated patients",
    "Each additional point associated with 48.7% increase in major bleeding risk",
    "Validated in multiple international cohorts including RE-LY, GARFIELD-AF, COMBINE-AF, and RAMQ",
    "Should be used to guide clinical decision-making regarding anticoagulation therapy",
    "Consider bleeding risk reduction strategies for moderate to very high risk patients"
  ]
}